M
Meltin MMI
Bio-signal processing and biologically inspired robotics technology
About Meltin MMI
Meltin MMI is a Japanese research and development company founded in 2013 by Masahiro Kasuya, Tatsuya Seki, Sumio Ito, Takahiro Uhicda, and Mizuki Komasa, with Masahiro Kasuya serving as CEO. The company specializes in cyborg technologies, integrating bio-signal processing with biologically inspired robotics. The founder's journey began at a young age; at three, Kasuya was already contemplating human limitations, leading him to explore the fusion of medicine and engineering by the age of ten and to begin research into cyborg technology in 2002. In 2011, he received the Robotics Society of Japan's Research Encouragement Award and later earned a Ph.D. in robotics and artificial intelligence engineering.
The company has two main product lines: avatar robots and medical devices. Its avatar robot, MELTANT, is designed to replicate human hand movements with dexterity, strength, and speed, allowing for remote operation in hazardous or distant environments. The concept model, MELTANT-α, was introduced in 2018, followed by MELTANT-β in 2020, an enhanced version for field testing in real-world work environments. This technology is being explored for applications in space by JAXA and ANA. The robot's hands are modeled on human muscle and tendon structures and use wire-driven mechanisms to achieve both powerful and delicate motions, such as holding an egg without breaking it. The system boasts a low latency of 0.02 seconds for real-time operability.
In the medical field, Meltin MMI developed the MELTz Hand Rehabilitation System, a certified medical device designed for neurorehabilitation. This system assists patients with finger paralysis, often resulting from strokes, by using AI to analyze myoelectric signals from the forearm. It reads the patient's intended movements and assists them, helping the brain to relearn motor functions. Meltin MMI operates on a business model focused on the R&D and commercialization of its technologies, collaborating with partners like Sumitomo Pharma for marketing and distribution. The company has raised a total of $20.1 million in funding over three rounds from investors including SBI Investment, Dai-ichi Life, and Sumitomo Dainippon Pharma.
Source: Dealroom company dataNews
Open roles
Meltin MMI in the Tokyo ecosystem
The Meltin MMI office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
UntroD Capital
Series A1 investor entered at this stage
Dainippon Sumitomo Pharma
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Meltin MMI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Meltin MMI on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


